Showing 5611-5620 of 9794 results for "".
- FDA Clears New Underarm Sweat Control Patchhttps://practicaldermatology.com/news/fda-clears-new-underarm-sweat-control-patch/2461660/The U.S. Food and Drug Administration (FDA) has cleared cleared Brella, the first 3-Minute SweatControl Patch to significantly reduce excessive underarm sweating in adults with primary axillary hyperhidrosis. The Brella SweatControl Patch provide
- Survey: Gen Z and Millennial Men Fall Short on Face Washing, Skin Carehttps://practicaldermatology.com/news/survey-gen-z-and-millennial-men-fall-short-on-face-washing-skin-care/2461656/Many Gen Z and millennial men would rather going on a bad date than take care of their skin, according to a new survey conducted by OnePoll on behalf of CeraVe. In a recent survey of 2,000 men ages 18–26 and 27–42, two in five (42%) revealed they need someone to confront the
- Millennials, Gen Xers Not Well-Schooled on Skin Cancer Preventionhttps://practicaldermatology.com/news/millennials-gen-xers-not-well-schooled-on-skin-cancer-prevention/2461648/Millennials and Gen Xers are racked with sun regrets, a new survey shows. Just 19% of millennials and Gen Xers wear sunscreen all year, 35% used a tanning bed, and 46% regretted how long they stayed out in the sun when they were younger. This is why
- Building a Better Sunscreen: Is Rosmarinic Acid the Key?https://practicaldermatology.com/news/building-a-better-sunscreen-is-rosmarinic-acid-the-key/2461646/Rosmarinic acid may enhance sunscreen efficacy without increasing concentration of conventional UV filters, a new study in Cosmetics suggests. When 0.1% Rosmarinic acid an active antioxidant was added
- Mount Sinai Wins $1.3M Grant to Expand Skin Biology Research Training Programhttps://practicaldermatology.com/news/mount-sinai-wins-13m-grant-to-expand-skin-biology-research-training-program/2461643/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai will expand its research training program in skin biology with support from a five-year, $1.3 million T32 grant from the National Institutes of Health (NIH) and the National Institute of Arth
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was
- Iovance Biotherapeutics Completes Biologics License Application Submission for Lifileucel in Advanced Melanomahttps://practicaldermatology.com/news/iovance-biotherapeutics-completes-biologics-license-application-submission-for-lifileucel-in-advanced-melanoma/2461633/Iovance Biotherapeutics announced it has completed its rolling Biologics License Application (BLA) submission to the FDA for lifileucel. Lifileucel is a tumor infiltrating lymphocyte (TIL) therapy intended as a treatment for patients with advanced (unresectable or metastatic) melanoma w
- New North Carolina Courage Jerseys to Feature Merz Aesthetics Sponsorshiphttps://practicaldermatology.com/news/new-north-carolina-courage-jerseys-to-feature-merz-aesthetics-sponsorship-1/2461632/Merz Aesthetics North America has launched its front-of-jersey sponsorship deal with the
- Phase 3 Studies Show Lebrikizumab Effective in Patients With Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/phase-3-studies-show-lebrikizumab-effective-in-patients-with-moderate-to-severe-atopic-dermatitis/2461630/After 16 weeks of treatment, lebrikizumab (Almirall) was effective in adolescents and adults with moderate-to-severe atopic dermatitis, according to two Phase 3 studies. The research was published in the New England Journal of